-
Does "Toxoplasma abscess" Properly Describe Brain Lesions Caused by Toxoplasma gondii? Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-09 José Ernesto Vidal,Amaro Nunes Duarte,Felicia C Chow,Maria Irma Seixas Duarte
-
Vaccine Development Should Be Polytheistic, Not Monotheistic Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-07 Stanley A Plotkin, James M Robinson, Joseph R A Fitchett, Edward Gershburg
Vaccines based on mRNA technology have been tremendously successful, but their properties are not necessarily ideal for all pathogens. There is a risk that concentration on that technology alone for new vaccine development will ignore older technologies that have properties giving broader and more persistent protection.
-
Adverse impact of azithromycin on the rectal microbiome. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-06 Sheeba Santhini Manoharan-Basil,Thibaut Vanbaelen,Chris Kenyon
-
Is More Always Better? Rethinking Monotherapy for Enterococcus faecalis Infective Endocarditis. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-06 Connor Prosty,Todd C Lee,Emily G McDonald
-
Adjunctive Therapy in Enterococcus faecalis Endocarditis Treatment: Maybe Less is Not Enough. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-06 Pierre Danneels,Jean-François Hamel,Vincent Dubée
-
Prospective exploratory evaluation of Cepheid Xpert Mycobacterium tuberculosis host response cartridge: a focus on adolescents and young adults Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-05 Marva Seifert, Donald G Catanzaro, Michael Gracia, Naomi Hillery, Sabira Tahseen, Faisal Masood, Alamdar Hussain, Uzma Majeed, Rebecca E Coleman, Rehan R Syed, Antonino Catanzaro, Timothy Rodwell
Background An accurate, rapid, non-sputum-based triage test for diagnosing tuberculosis (TB) is needed. Methods A prospective evaluation of the Xpert-MTB-HR cartridge, a prototype blood-based host-response mRNA signature assay, among individuals presenting with TB-like symptoms was performed in Pakistan and results were compared to three reference standards: Xpert MTB/RIF Ultra, bacteriological confirmation
-
Outcomes of Adjunctive Corticosteroid Treatment on Hypoxemic Adults Hospitalised for Mycoplasma pneumoniae Pneumonia: a Retrospective Cohort Study Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-05 Karl Hagman, Anna C Nilsson, Magnus Hedenstierna, Johan Ursing
Background Corticosteroids appears to be beneficial for severe Mycoplasma pneumoniae pneumonia in children but data in adults are limited. This study investigated effects of adjunctive corticosteroids in hypoxemic adults with M. pneumoniae pneumonia. Methods Adults admitted 2013-2017 with verified M. pneumoniae pneumonia and hypoxemia (SpO2<93% or oxygen treatment) were included in a cohort. Treatment
-
DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor–based Regimen Switch Strategy to Manage Integrase Inhibitor–related Weight Gain Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-05 David Anderson, Moti Ramgopal, Debbie P Hagins, Johnnie Lee, Richard Bruce Simonson, Tien-Huei Hsu, Ping Xu, Nina Ahmad, William R Short
Background Integrase strand transfer inhibitor (InSTI)-based antiretroviral therapies have been associated with greater weight gain in people living with HIV versus on protease inhibitor (PI)-based regimens. The DEFINE study investigated whether switching from an InSTI- to a PI-based regimen could mitigate/reverse weight gain. Methods DEFINE (NCT04442737) was a randomized, 48-week, open-label, prospective
-
Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-02 Ahizechukwu C Eke,Sean S Brummel,Muktar H Aliyu,Lynda Stranix-Chibanda,George U Eleje,Ifeanyichukwu U Ezebialu,Violet Korutaro,Deo Wabwire,Allen Matubu,Tapiwa Mbengeranwa,Nahida Chakhtoura,Lameck Chinula,Katie McCarthy,Kevin Knowles,Chelsea Krotje,Macrae F Linton,Kelly E Dooley,Paul E Sax,Todd Brown,Shahin Lockman,
OBJECTIVE Tenofovir alafenamide (TAF)-based antiretroviral therapy (ART) regimens have been associated with adverse changes in lipid and glucose profiles compared with tenofovir disoproxil fumarate (TDF)-based ART, but data in pregnancy is limited. We evaluated metabolic markers in pregnant women with HIV after starting TAF- vs TDF-based ART. METHODS We analyzed data within the IMPAACT 2010/VESTED
-
Stepping with Caution: Large Language Models for Consulting Infectious Diseases. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-02 Partha Pratim Ray
-
Is strong AI skepticism justified or counterproductive? Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-02 Thomas Hänscheid,Martin P Grobusch
-
Safe implementation of large language models in clinical care requires acknowledgment of their limitations and strong regulation to prevent misuse. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-09-02 Nicolás Cortés-Penfield,Ilan S Schwartz
-
Incidence and risk factors for invasive fungal infections in patients initiating TNF-alpha inhibitors for inflammatory bowel disease and rheumatoid arthritis Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-31 Ian Hennessee, Kaitlin Benedict, Nathan C Bahr, Shari R Lipner, Jeremy A W Gold
In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an IFI within one year of initiating TNF-alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.
-
Potential implications of using locally validated risk factors for drug-resistant pathogens in patients with community-acquired pneumonia in US hospitals: A cross-sectional study Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-30 Hamlet Gasoyan, Abhishek Deshpande, Peter B Imrey, Ning Guo, Benjamin G Mittman, Michael B Rothberg
Background The 2019 ATS/IDSA community-acquired pneumonia (CAP) guidelines recommend that clinicians prescribe empiric antibiotics for MRSA or P. aeruginosa only if locally validated risk factors (or 2 generic risk factors if local validation is not feasible) are present. It remains unknown how implementation of this recommendation would influence care. Methods This cross-sectional study included adults
-
Diverse Sources and Latent Reservoirs of Community-Associated Clostridioides difficile Infection Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-29 Ahmad F Alshannaq, Ashley E Kates, Julie A Keating, Linda L Mckinley, Jonah W Dixon, Nasia Safdar
Clostridioides difficile (C. difficile) is a spore-forming, toxin-producing, anaerobic bacterium infecting the human gastrointestinal tract, causing diarrhea and life-threatening colitis. C. difficile epidemiology continues to evolve, and it is recognized as a major community-associated pathogen in addition to its established role in causing healthcare-associated infection. While current surveillance
-
The risk of non-AIDS defining events is lower in ART-naive HIV controllers than in normal progressors on suppressive ART Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-29 Albert L Groenendijk, Pedro Miranda Afonso, Ferdinand Wit, Martinus J T Blaauw, Louise E van Eekeren, Twan Otten, Wilhelm A J W Vos, Nadira Vadaq, Jéssica C dos Santos, Jan van Lunzen, Andre van der Ven, Casper Rokx, Annelies Verbon
Background We aimed to compare the non-AIDS events (nADE) risk between normal progressors using ART (NP-ART) and people with HIV (PWH) that naturally control HIV infection (HIV controllers), as well as the outcomes after ART in HIV controllers on nADE. Methods The primary endpoint was major nADE defined as the composite of cardiovascular disease, non-AIDS malignancy or all-cause mortality, whichever
-
Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-29 Onyema Ogbuagu, Jean-Michel Molina, Ploenchan Chetchotisakd, Moti N Ramgopal, William Sanchez, Jason Brunetta, Francesco Castelli, Gordon E Crofoot, Chien-Ching Hung, Sylvie Ronot-Bregigeon, Nicolas A Margot, Hui Wang, Hadas Dvory-Sobol, Martin S Rhee, Sorana Segal-Maurer
Background Lenacapavir is a long-acting HIV-1 capsid inhibitor for treatment of HIV-1 infection. We evaluated the efficacy and safety of lenacapavir in combination with an investigator-selected optimized background regimen (OBR) after 104 weeks in adults with multidrug-resistant HIV-1. Methods This ongoing, international, Phase 2/3 trial at 42 sites included 72 adults living with multidrug-resistant
-
A New Era of Targeted Clinical Guidelines: Launching the IDSA Guidelines Supplement. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-28 Nabin K Shrestha,Jonathan L Heald,Sarah Pahlke,Genet Demisashi,Sharon Weissman
-
A Different (My) Side of the Opioid and Drug Crisis. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-28 Aldo Barajas-Ochoa
-
Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-28 Chandrasekaran Padmapriyadarsini,Vikas S Oswal,Chetankumar D Jain,Muthu Vijayalakshmi Mariappan,Neeta Singla,Santosh Kumar,Bella Devaleenal Daniel,Jigna D Dave,Parul Vadgama,Balaji Ramraj,Surya Kant,Anuj K Bhatnagar,Sivakumar Shanmugam,Dhamodharan Paul,Jeyadeepa Bharathi,Manasi Palav,Neha V Shah,Rameshkumar Santhanakrishnan,Ravindra K Dewan,Nadim Shekh,Prabhakaran Rathinam,Arvind B Sisara,Shubhangi
BACKGROUND Treatment of drug-resistant tuberculosis with bedaquiline-pretomanid-linezolid regimen has demonstrated good treatment efficacy. Given linezolid's toxicity profile, prudence suggests reconsidering its dose and duration. We determined the effectiveness and safety of structured dose reduction of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant (pre-XDR)
-
Clinical impact of pleural fluid Streptococcus pneumoniae PCR testing in children with complicated pneumonia Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-28 Erin C Ho, Kaitlin E Olson, Molly Butler, Meghan Birkholz, Kristen Miller, Christine E MacBrayne, Sarah Jung, Kevin Messacar, Edwin J Asturias, Samuel R Dominguez
Background While Streptococcus pneumoniae (Spn) is the leading cause of pediatric complicated community acquired pneumonia (cCAP), it is infrequently recovered by culture-based methods. We studied the real-world clinical impact of an Spn PCR assay for pleural fluid. Methods This pre-post quasi-experimental cohort study compared pathogen detection, antibiotic usage, and outcomes in children hospitalized
-
Prosthetic Joint Infections due to Candida Species: A Multicenter International Study. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-27 Aurélien Dinh,Martin McNally,Emma D'Anglejan,Christel Mamona Kilu,Julie Lourtet,Rosemary Ho,Matthew Scarborough,Maria Dudareva,Gerald Jesuthasan,Cecile Ronde Oustau,Stéphane Klein,Laura Escolà-Vergé,Dolores Rodriguez Pardo,Pierre Delobel,Jaime Lora-Tamayo,Mikel Mancheño-Losa,Maria Luisa Sorlí Redó,José María Barbero Allende,Cédric Arvieux,Danguole Vaznaisiène,Thomas Bauer,Anne-Laure Roux,Latifa Noussair
BACKGROUND Prosthetic joint infection (PJI) caused by Candida spp is a severe complication of arthroplasty. We investigated the outcomes of Candida PJI. METHODS This was a retrospective observational multinational study including patients diagnosed with Candida-related PJI between 2010 and 2021. Treatment outcome was assessed at 2-year follow-up. RESULTS A total of 269 patients were analyzed. Median
-
Evaluation of C-Reactive Protein and Computer-Aided Analysis of Chest X-rays as Tuberculosis Triage Tests at Health Facilities in Lesotho and South Africa Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-27 Shannon Bosman, Irene Ayakaka, Josephine Muhairwe, Mashaete Kamele, Alastair van Heerden, Thandanani Madonsela, Niklaus D Labhardt, Gregor Sommer, Jens Bremerich, Thomas Zoller, Keelin Murphy, Bram van Ginneken, Alfred K Keter, Bart K M Jacobs, Moniek Bresser, Aita Signorell, Tracy R Glass, Lutgarde Lynen, Klaus Reither
Background To improve tuberculosis case-finding, rapid, non-sputum triage tests need to be developed according to the World Health Organization target product profile (TPP) (>90% sensitivity, >70% specificity). We prospectively evaluated and compared artificial intelligence–based, computer-aided detection software, CAD4TBv7, and C-reactive protein assay (CRP) as triage tests at health facilities in
-
A phase III randomized controlled trial of plitidepsin, a marine derived compound, in hospitalized adults with moderate COVID-19 Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-26 Pedro Landete, Olga-Adriana Caliman-Sturdza, Jose A Lopez-Martin, Liliana Preotescu, Mihaela-Catalina Luca, Anastasia Kotanidou, Paula Villares, Shirley-Patricia Iglesias, Pablo Guisado-Vasco, Elena-Maria Saiz-Lou, Maria del Carmen Farinas-Alvarez, Esperanza Merino de Lucas, Eduardo Perez-Alba, Jose-Miguel Cisneros, Vicente Estrada, Carmen Hidalgo-Tenorio, Garyfallia Poulakou, Miguel Torralba, Jesus
Background Plitidepsin has shown potent preclinical activity against SARS-CoV-2 and was generally well tolerated in a Phase I trial of hospitalized patients with COVID-19. NEPTUNO, a Phase III, multicenter, randomized, controlled trial, was designed to evaluate the efficacy and safety of plitidepsin in the management of moderate COVID-19 in hospitalized adult patients. Methods Included patients had
-
The Impact of Infectious Diseases Scholarly Mentorship on Subsequent Infectious Disease Fellowship Application. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-24 Joseph E Marcus,Heather C Yun,Alice E Barsoumian
INTRODUCTION Infectious diseases physicians invest significant time mentoring medical students and internal medicine residents through research projects as well as case reports. While having an infectious diseases mentor has been shown to be associated with subsequent infectious diseases fellowship application, the impact of specific scholarly activities on future application to infectious diseases
-
The end of toxoid vaccine development for preventing Clostridioides difficile infections? Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-24 Ed J Kuijper,Dale N Gerding
-
Implementation of single high-dose liposomal amphotericin B based induction therapy for treatment of HIV-associated cryptococcal meningitis in Uganda: a comparative prospective cohort study Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-24 Jane Gakuru, Enock Kagimu, Biyue Dai, Samuel Okurut, Laura Nsangi, Nathan C Bahr, Michael Okirwoth, Olivie C Namuju, Joseph N Jarvis, David S Lawrence, Cynthia Ahimbisibwe, Jayne Ellis, Kizza Kandole Tadeo, David R Boulware, David B Meya, Lillian Tugume
Background In 2022, the World Health Organization (WHO) recommended a single 10mg/kg dose of liposomal amphotericin B in combination with 14 days of flucytosine and fluconazole (AMBITION-cm regimen) for induction therapy of HIV-associated cryptococcal meningitis, based on the results of the multisite AMBITION-cm trial. We evaluated outcomes after real-world implementation of this novel regimen in Uganda
-
CLOVER: A Phase 3 Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-24 Curtis J Donskey, Erik R Dubberke, Nicola P Klein, Elizabeth G Liles, Katarzyna Szymkowiak, Mark H Wilcox, Jody Lawrence, Salim Bouguermouh, Haiying Zhang, Kenneth Koury, Ruth Bailey, Helen M Smith, Stephen Lockhart, Erik Lamberth, Warren V Kalina, Michael W Pride, Chris Webber, Annaliesa S Anderson, Kathrin U Jansen, William C Gruber, Nicholas Kitchin
Background Clostridioides difficile infection (CDI) causes substantial mortality and healthcare burden. We assessed the detoxified toxin-A/B PF-06425090 vaccine for primary CDI prevention. Methods This phase 3 observer-blinded study randomized (1:1) ≥50-year-olds at increased CDI risk (N=17,535) to receive 3 PF-06425090 or placebo doses (0,1,6-months). Primary endpoints were first CDI episode (≥3 unformed
-
Chances/Challenges of the Role of New Beta-lactamase Inhibitors Against the Growing Threat of NDM-producing Escherichia coli With Penicillin-binding Protein 3 Mutations. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-23 Claudia Fabrizio,Carlo Tascini
-
PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent Clostridioides difficile infection Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-23 Paul Feuerstadt, Teena Chopra, Whitfield Knapple, Nicholas W Van Hise, Erik R Dubberke, Brian Baggott, Beth Guthmueller, Lindy Bancke, Michael Gamborg, Theodore S Steiner, Daniel Van Handel, Sahil Khanna
Objective To evaluate the safety and efficacy of fecal microbiota, live-jslm (RBL; REBYOTA) – the first single-dose, broad consortia microbiota-based live biotherapeutic approved by the United States (US) Food and Drug Administration for preventing recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care (SOC) antibiotic treatment. Design PUNCH CD3-OLS was a prospective
-
Critical Considerations for PCR Diagnostics in Pneumocystis Pneumonia Detection. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-22 Lu Hao,Chen He
-
Timing of influenza antiviral therapy and risk of death in adults hospitalized with influenza-associated pneumonia, FluSurv-NET, 2012-2019 Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-22 Mark W Tenforde, Kameela P Noah, Alissa C O’Halloran, Pam Daily Kirley, Cora Hoover, Nisha B Alden, Isaac Armistead, James Meek, Kimberly Yousey-Hindes, Kyle P Openo, Lucy S Witt, Maya L Monroe, Patricia A Ryan, Anna Falkowski, Libby Reeg, Ruth Lynfield, Melissa McMahon, Emily B Hancock, Marisa R Hoffman, Suzanne McGuire, Nancy L Spina, Christina B Felsen, Maria A Gaitan, Krista Lung, Eli Shiltz, Ann
Background Pneumonia is common in adults hospitalized with laboratory-confirmed influenza, but the association between timeliness of influenza antiviral treatment and severe clinical outcomes in patients with influenza-associated pneumonia is not well characterized. Methods We included adults aged ≥18 years hospitalized with laboratory-confirmed influenza and a discharge diagnosis of pneumonia over
-
Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults ≥65 Years of Age Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-22 Jennifer H Ku, Emily Rayens, Lina S Sy, Lei Qian, Bradley K Ackerson, Yi Luo, Julia E Tubert, Gina S Lee, Punam P Modha, Yoonyoung Park, Tianyu Sun, Evan J Anderson, Hung Fu Tseng
Background Influenza causes substantial morbidity, particularly among older individuals. Updated data on the effectiveness of currently licensed vaccines in this population are needed. Methods At Kaiser Permanente Southern California, we conducted a retrospective cohort study to evaluate comparative vaccine effectiveness (cVE) of high-dose (HD), adjuvanted, and standard-dose (SD) cell-based influenza
-
Application of Diagnostic Stewardship to Fungal Polymerase Chain Reaction: Low Yield of Follow-up Testing on Plasma and Bronchoalveolar Lavage After a Negative Result. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-20 Tong Wang,Bosung Park,Gavin Anderson,Brian Shaller,Indre Budvytiene,Niaz Banaei
BACKGROUND Early diagnosis of invasive fungal disease is essential for optimizing management. Although the clinical utility of fungal polymerase chain reaction (PCR) testing on plasma and bronchoalveolar lavage (BAL) has been established, the role of follow-up testing remains unclear. METHODS This was a retrospective single-center study. The yield of follow-up PCR for Aspergillus species, Mucorales
-
Association between SARS-CoV-2 infection during pregnancy and gestational diabetes: a claims-based cohort study. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-19 Oscar Rincón-Guevara,Bailey Wallace,Lyudmyla Kompaniyets,Catherine E Barrett,Lara Bull-Otterson
INTRODUCTION Coronavirus disease 2019 (COVID-19) may be associated with gestational diabetes mellitus (GDM); however, evidence is limited by sample sizes and lack of control groups. METHODS To assess the GDM risk after COVID-19 in pregnancy, we constructed a retrospective cohort of pregnancies ending March 2020-October 2022 using medical claims. People with COVID-19 diagnosis claims from conception
-
Population-Specific Urinalysis Parameters are Necessary to Improve Diagnostic Value for Urinary Tract Infection. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-19 Milner Staub,Jessica Bennett,Kelly W Davis,Jeffrey W Jansen
-
Safety and Immunogenicity of an mRNA-1273 Booster in Children. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-19 Vladimir Berthaud,C Buddy Creech,Christina A Rostad,Quito Carr,Liberation De Leon,Monika Dietrich,Anil Gupta,David Javita,Sharon Nachman,Swetha Pinninti,Mobeen Rathore,Carina A Rodriguez,Katherine Luzuriaga,William Towner,Anne Yeakey,Mollie Brown,Xiaoping Zhao,Weiping Deng,Wenqin Xu,Honghong Zhou,Bethany Girard,Roxanne Kelly,Karen Slobod,Evan J Anderson,Rituparna Das,Jacqueline Miller,Sabine Schnyder
BACKGROUND A 2-dose mRNA-1273 primary series in children aged 6 months-5 years (25-µg) and 6-11 years (50-µg) had an acceptable safety profile and was immunogenic in the phase 2/3 KidCOVE study. We present data from KidCOVE participants who received an mRNA-1273 booster dose. METHODS An mRNA-1273 booster dose (10-µg for children aged 6 months-5 years; 25-µg for children aged 6-11 years; age groups
-
Time for OPAT coordination: difficult to quantify due to heterogeneity in OPAT care models. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-19 Bryan P White,Maria Alkozah,Emily A Siegrist
-
Pitavastatin is Well-Tolerated with no Detrimental Effects on Physical Function Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-19 Kristine M Erlandson, Triin Umbleja, Heather J Ribaudo, Jennifer A Schrack, Edgar T Overton, Carl J Fichtenbaum, Kathleen V Fitch, Jhoanna C Roa, Marissa R Diggs, Kenneth Wood, Markella V Zanni, Gerald S Bloomfield, Carlos Malvestutto, Judith A Aberg, Maria C Rodriguez-Barradas, Rosalba Gomez Morones, Katherine Breaux, Pamela S Douglas, Steven K Grinspoon, Todd T Brown
Background Little is known about the potential benefits or harms of statins on physical function among people with HIV (PWH). Methods REPRIEVE was a double-blind randomized controlled trial evaluating pitavastatin for primary prevention of major adverse cardiovascular events (MACE) in PWH. Time to complete ten chair rises, 4-meter gait speed, grip strength, and a modified short physical performance
-
Preventability of Hospital Deaths in Patients with Non-Ventilator Hospital-Acquired Pneumonia Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-19 Alexander M Tatara, Anna Apostolopoulou, Anna A Agan, Laura DelloStritto, Chanu Rhee, Michael Klompas
Background Crude and adjusted mortality rates for patients with non-ventilator hospital-acquired pneumonia (NV-HAP) are amongst the highest of all healthcare-associated infections, leading to calls for greater prevention. Patients prone to NV-HAP, however, tend to be severely ill at baseline making it unclear whether their high mortality rates are due to NV-HAP, underlying conditions, or both. Methods
-
Models of OPAT Care: One Size May Not Fit All. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-17 Asher J Schranz,Claire E Farel,Teresa Oosterwyk,Angela Perhac,Alan C Kinlaw
-
A 73-year-old Japanese Woman With Rheumatoid Arthritis and Exposure to Water From a Well. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-16 Shinsuke Kikuchi,Yoshihiko Saito,Takahisa Tateishi,Ken-Ichi Irie,Tatsuya Imai,Makoto Morimitsu,Erina Iwanaga,Matthew R Watts,Takayuki Taniwaki,Ichizo Nishino
-
Executive Summary: State-of-the-Art Review: Evaluation and Management of Delusional Infestation. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-16 Alexandra Mendelsohn,Taisuke Sato,Ankita Subedi,Alysse G Wurcel
-
State-of-the-Art Review: Evaluation and Management of Delusional Infestation. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-16 Alexandra Mendelsohn,Taisuke Sato,Ankita Subedi,Alysse G Wurcel
Delusional infestation is a condition encountered frequently by healthcare professionals across a variety of specialties in which patients have a fixed, false belief that they are infested with living creatures, such as bugs, parasites, worms, or mites, or nonliving objects, such as fibers. Delusional infestation can be debilitating for patients, who not only present with intense psychological distress
-
Food Insecurity at Tuberculosis Treatment Initiation Is Associated With Clinical Outcomes in Rural Haiti: A Prospective Cohort Study. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-16 Aaron Richterman,Elie Saintilien,Medgine St-Cyr,Louise Claudia Gracia,Sara Sauer,Inobert Pierre,Moise Compere,Ahmed Elnaiem,Dyemy Dumerjuste,Louise C Ivers
BACKGROUND Tuberculosis is a leading cause of death worldwide, and food insecurity is known to negatively influence health outcomes through multiple pathways. Few studies have interrogated the relationship between food insecurity and tuberculosis outcomes, particularly independent of nutrition. METHODS We conducted a prospective cohort study of adults initiating first-line treatment for clinically
-
Hepatitis B-CpG Vaccine Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-16 Rachel K Russ,Haley M Vandehei,Maria I Golovkina,Harshitha Mogallapalli,Freddy Caldera,Mary S Hayney
This prospective study enrolled healthcare workers (HCWs) who were nonresponders following at least 5 doses of aluminum-adjuvanted hepatitis B vaccine who received the 2-dose Heplisav-B (HepB-CpG) (Dynavax Technologies Corporation, Emeryville, CA) series. After 2 doses of HepB-CpG, 43/47 (91%) participants, and with 1 dose, 41/49 (84%) responded. HepB-CpG could be the preferred vaccine in HCW nonresponders
-
Evaluation of the HANDOC Score and the 2023 International Society of Cardiovascular Infectious Diseases and European Society of Cardiology Duke Clinical Criteria for the Diagnosis of Infective Endocarditis Among Patients With Streptococcal Bacteremia. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-16 Nicolas Fourré,Virgile Zimmermann,Laurence Senn,Pierre Monney,Georgios Tzimas,Giorgia Caruana,Piergiorgio Tozzi,Matthias Kirsch,Benoit Guery,Matthaios Papadimitriou-Olivgeris
BACKGROUND Streptococci are a common cause of infective endocarditis (IE). We aimed to evaluate the performance of the HANDOC score to identify patients at high risk for IE and the Duke clinical criteria of the European Society of Cardiology (ESC; 2015 and 2023 versions) and the 2023 version from the International Society of Cardiovascular Infectious Diseases (ISCVID) in diagnosing IE among patients
-
The Value of Outpatient Parenteral Antimicrobial Therapy: Better Care in 27 Minutes. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-16 Addison S Hicks,Joshua C Eby
-
The Effect of COVID-19 Vaccination on Outpatient Antibiotic Prescribing in Older Adults: A Self-Controlled Risk-Interval Study. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-16 Sarah C J Jorgensen,Kevin Brown,Anna E Clarke,Kevin L Schwartz,Colleen Maxwell,Nick Daneman,Jeffrey C Kwong,Derek R MacFadden
BACKGROUND Coronavirus disease 2019 (COVID-19) vaccination has been associated with reduced outpatient antibiotic prescribing among older adults with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the impact of COVID-19 vaccination on outpatient antibiotic prescribing in the broader population of older adults, regardless of SARS-CoV-2 infection status
-
Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-16 Carolyn T Bramante,Kenneth B Beckman,Tanvi Mehta,Amy B Karger,David J Odde,Christopher J Tignanelli,John B Buse,Darrell M Johnson,Ray H B Watson,Jerry J Daniel,David M Liebovitz,Jacinda M Nicklas,Ken Cohen,Michael A Puskarich,Hrishikesh K Belani,Lianne K Siegel,Nichole R Klatt,Blake Anderson,Katrina M Hartman,Via Rao,Aubrey A Hagen,Barkha Patel,Sarah L Fenno,Nandini Avula,Neha V Reddy,Spencer M Erickson
BACKGROUND Metformin has antiviral activity against RNA viruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The mechanism appears to be suppression of protein translation via targeting the host mechanistic target of rapamycin pathway. In the COVID-OUT randomized trial for outpatient coronavirus disease 2019 (COVID-19), metformin reduced the odds of hospitalizations/death
-
Repurposing Revisited: Exploring the Role of Metformin for Treatment of COVID-19. Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-16 Mark J Siedner,Paul E Sax
-
The Ethical Obligation to Treat Infectious Patients: A Systematic Review of Reasons Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-16 Braylee Grisel, Kavneet Kaur, Sonal Swain, Laura Gorenshtein, Chinecherem Chime, Ellen O’Callaghan, Avani Vasireddy, Lauren Moore, Christina Shin, Michelle Won, Santita Ebangwese, Todd Tripoli, Stephanie Lumpkin, Zachary Ginsberg, Sarah Cantrell, Jennifer Freeman, Suresh Agarwal, Krista Haines
During pandemics, healthcare providers struggle with balancing obligations to self, family, and patients. While HIV/AIDS seemed to settle this issue, coronavirus disease 2019 (COVID-19) rekindled debates regarding treatment refusal. We searched MEDLINE, Embase, CINAHL Complete, and Web of Science using terms including obligation, refusal, HIV/AIDS, COVID-19, and pandemics. After duplicate removal and
-
Association of weather variables with pathogens contributing to conjunctivitis worldwide Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-15 Daisy Yan, N Venkatesh Prajna, Prajna Lalitha, Wiwan Sansanayudh, Vannarut Satitpitakul, Wipada Laovirojjanakul, Meenu Chaudhary, Mamadou Bountogo, Ali Sie, Boubacar Coulibaly, Abdou Amza, Beido Nassirou, Ibrahim Almou, Huy Tran, Yen Tran, Edmund Tsui, Tania Onclinx, Ruti Sella, Lee Goren, Esmeralda McClean, Vivien Tham, Cindi Chen, Kevin Ruder, Lina Zhong, YuHeng Liu, Danny Yu, Thomas Abraham, Elodie
Purpose To identify weather variables associated with pathogens contributing to infectious conjunctivitis globally. Methods Sample collection and pathogen identification from patients with acute infectious conjunctivitis was performed from 2017 to 2023. We linked pathogens identified from 13 sites across 8 countries with publicly available weather data by geographic coordinates. Mixed effects logistic
-
Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational Study Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-14 Sanjay Jayasinghe, Phoebe C M Williams, Kristine K Macartney, Nigel W Crawford, Christopher C Blyth
Background In mid-2018, the Australian childhood 13-valent pneumococcal conjugate vaccine schedule changed from 3+0 to 2+1, moving the third dose to 12 months of age, to address increasing breakthrough cases of invasive pneumococcal disease (IPD), predominantly in children aged >12 months. This study assessed the impact of this change using national IPD surveillance data. Methods Pre- and postschedule
-
Factors Associated with Poor Clinical and Microbiologic Outcomes in C. auris Bloodstream Infection: A Multicenter Retrospective Cohort Study Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-13 Adriana Jimenez, Rossana Rosa, Samantha Ayoub, Rachel Guran, Sebastian Arenas, Nickolas Valencia, Janna C Stabile, Adrian T Estepa, Dipen J Parekh, Tanira Ferreira, Hayley B Gershengorn, Kavitha K Prabaker, Paula A Eckardt, Matthew Zahn, Lilian M Abbo, Bhavarth S Shukla
Background C. auris has become a growing concern worldwide due to increases in incidence of colonization and reports of invasive infections. There are limited data on clinical factors associated with poor outcomes in patients with C. auris bloodstream infection (BSI). Methods We assembled a multicenter retrospective cohort of patients with C. auris BSI from two geographics areas in US healthcare settings
-
Rapid Implementation of Blood Culture Stewardship: Institutional Response to an Acute National Blood Culture Bottle Shortage Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-11 Romney M Humphries, Patty W Wright, Ritu Banerjee, Daniel E Dulek, John C Champion, David C Gaston, Thomas R Talbot
We describe our approach to addressing a nationwide supply issue for blood culture bottles. Aerobic blood culture bottles received from our distributor during 1–15 July 2024 were <1% of typical usage. Through education and ordering restrictions of blood culture, designed to minimize risk, orders were reduced by 49% over a 1-week period.
-
Single monoclonal antibodies should not be used for COVID-19 therapy: a call for antiviral stewardship Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-08 Arturo Casadevall, Daniele Focosi, Liise-anne Pirofski, Shmuel Shoham
The COVID-19 pandemic saw the largest deployment of monoclonal antibodies (mAbs) for an infectious disease in history. mAbs to SARS-CoV-2 spike protein proved safe and were initially effective for COVID-19 therapy, but each was defeated by continued SARS-CoV-2 evolution, leading to their withdrawal. This was a setback for people with impaired immunity who cannot mount an effective antibody response
-
Integrase strand transfer inhibitor (INSTI) related changes in BMI and risk of diabetes: a prospective study from the RESPOND cohort consortium Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-07 Dhanushi Rupasinghe, Loveleen Bansi-Matharu, Matthew Law, Robert Zangerle, Andri Rauch, Philip E Tarr, Lauren Greenberg, Bastian Neesgaard, Nadine Jaschinski, Stéphane De Wit, Ferdinand Wit, Antonella d'Arminio Monforte, Eric Fontas, Antonella Castagna, Melanie Stecher, Vanessa Brandes, Eric Florence, Josip Begovac, Cristina Mussini, Anders Sönnerborg, Akaki Abutidze, Ana Groh, Vani Vannappagari, Cal
Background With integrase strand transfer inhibitor (INSTI) use associated with increased body mass index (BMI) and BMI increases associated with higher diabetes mellitus (DM) risk, this study explored the relationship between INSTI/non-INSTI regimens, BMI changes, and DM risk. Methods RESPOND participants were included if they had CD4, HIV RNA, and ≥ 2 BMI measurements during follow up. Those with
-
Hospital- and Ventilator-associated Pneumonia early after Lung Transplantation: a prospective Study on Incidence, Pathogen Origin and Outcome Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-07 Laura N Walti, Chun Fai Ng, Qasim Mohiuddin, Roni Bitterman, Mohammed Alsaeed, William Klement, Tereza Martinu, Aman Sidhu, Tony Mazzulli, Laura Donahoe, Shaf Keshavjee, Lorenzo del Sorbo, Shahid Husain
Background Hospital- (HAP) and ventilator-associated pneumonia (VAP) are important complications early (<30 days) after lung transplantation (LT). However, current incidence, associated factors and outcomes are not well reported. Methods LT recipients transplanted at our institution (07/2019-01/2020 and 10/2021-11/2022) were prospectively included. We assessed incidence and presentation of pneumonia
-
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024 Clin. Infect. Dis. (IF 8.2) Pub Date : 2024-08-07 Kevin C Ma, Diya Surie, Adam S Lauring, Emily T Martin, Aleda M Leis, Leigh Papalambros, Manjusha Gaglani, Christie Columbus, Robert L Gottlieb, Shekhar Ghamande, Ithan D Peltan, Samuel M Brown, Adit A Ginde, Nicholas M Mohr, Kevin W Gibbs, David N Hager, Safa Saeed, Matthew E Prekker, Michelle Ng Gong, Amira Mohamed, Nicholas J Johnson, Vasisht Srinivasan, Jay S Steingrub, Akram Khan, Catherine L
Background Assessing variant-specific COVID-19 vaccine effectiveness (VE) and severity can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collectively as “JN lineages”), emerged in late 2023 and exhibited substantial divergence from co-circulating XBB lineages. Methods We analyzed patients hospitalized with COVID-19–like